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ABSTRACT To probe the interaction between transducin (Gt) and photoactivated rhodopsin (R*), 14 analog peptides were
designed and synthesized restricting the backbone of the R*-bound structure of the C-terminal 11 residues of Gt derived by
transferred nuclear Overhauser effect (TrNOE) NMR. Most of the analogs were able to bind R*, supporting the TrNOE structure.
Improved affinities of constrained peptides indicated that preorganization of the bound conformation is beneficial. Cys347 was
found to be a recognition site; particularly, the free sulfhydryl of the side chain seems to be critical for R* binding. Leu349 was
another invariable residue. Both Ile and tert-leucine (Tle) mutations for Leu349 significantly reduced the activity, indicating that the
Leu side chain is in intimate contact with R*. The structure of R* was computer generated by moving helix 6 from its position in the
crystal structure of ground-state rhodopsin (R) based on various experimental data. Seven feasible complexes were found when
docking the TrNOE structure with R* and none with R. The analog peptides were modeled into the complexes, and their binding
affinities were calculated. The predicted affinities were compared with the measured affinities to evaluate the modeled structures.
Three models of the R*/Gt complex showed strong correlation to the experimental data.
INTRODUCTION
G-protein-coupled receptors (GPCRs) are integral mem-
brane proteins that transduce an extracellular event to an
intracellular signal and are vitally important to many phys-
iological functions, such as vision, olfaction, taste, and
endocrine signaling. The primary intracellular interaction of
a GPCR occurs with a signal-transducing, heterotrimeric
G-protein, consisting of , , and  subunits. The binding of
an activated GPCR to the G catalyzes exchange of GTP
for GDP bound to G. The G then leaves the GPCR as
G-GTP and G complex, both of which can trigger the
proper intracellular events. Although the overall pathway is
well established, the G-protein activation mechanism at
atomic resolution remains unclear. A number of human
diseases are characterized by mutations in GPCRs, and a
large fraction of the therapeutic compounds in use are
thought to interact with GPCRs. Understanding the interac-
tion between a GPCR and its G-protein in detail potentially
leads to a rational design of drugs to control the activities of
GPCRs. The lack of structural information has hindered us
from an atomic view of the interactions in the complex.
Crystal structures of various G-proteins (Coleman and
Sprang, 1998; Lambright et al., 1996; Tesmer et al., 1997;
Wall et al., 1995) and dark-adapted rhodopsin, the GPCR in
vision (R), have been solved (Palczewski et al., 2000).
Direct determination of the structure of an activated GPCR
or its complex, the signal-transducing state, has been im-
peded by lack of availability and/or stability of activated
GPCRs, including rhodopsin.
Molecular modeling is an alternative way to estimate protein
structure. Its ability to predict tertiary structures has improved
due to the better algorithms, scoring functions based on rapidly
expanding crystal-structure data, and increasing computer
power (Moult et al., 1999). Prediction of small protein loops in
homology modeling has seen significant progress (Galak-
tionov et al., 2001). Several molecular-docking programs
(Gabb et al., 1997; Goodsell and Olson, 1990; Meng et al.,
1992; Vakser, 1996) have been shown to find correct binding
sites from separate structures of receptors and their ligands.
Based on the vast biochemical studies that have been carried
out on the interactions between many different GPCRs and
G-proteins, we believe that molecular modeling has a potential
to integrate the diverse experimental observations and con-
struct feasible models of the interface between G-proteins and
their receptors.
Rhodopsin-transducin (Gt) is the typical, and the most
extensively studied, G-protein-linked signal transduction
system. Light triggers the signaling cascade with photoi-
somerization of 11-cis retinal, a small-molecule chro-
mophore covalently attached to Lys296 of rhodopsin, into
the all-trans form. Rhodopsin undergoes conformational
changes into the activated state (R*) that can bind and
activate Gt. The activation of rhodopsin and the binding of
Gt can be monitored by UV/visible spectroscopy. The ab-
sorbance peak of rhodopsin shifts from 500 nm (R) to an
equilibrium between 490 nm (Meta I) and 380 nm (Meta II)
upon activation, and the binding of Gt stabilizes Meta II and
shifts the equilibrium toward 380 nm. To understand the
Gt-activation mechanism, the structural change during
R3R* needs to be determined first and then the binding of
Gt to rhodopsin can be modeled as Gt binds only to R*.
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As to the conformational change, Farrens et al. (1996)
proposed rigid motion of helix 6 based on electron para-
magnetic resonance (EPR) experiments measuring distances
between residues on the cytoplasmic ends of helix 3 and
helix 6 during light activation. Tracing the movement of
retinal analogs in rhodopsin by photoaffinity as rhodopsin
changed its absorbance peak from 500 nm to 380 nm,
Borhan et al. (2000) found that the ionone ring of the retinal
cross-linked to Trp265 on helix 6 in R and to Ala169 on
helix 4 in R*. They suggested that helix 4 had to rotate
slightly to orient Ala169 toward the ionone ring, and helix
3 had to move because the all-trans retinal would have
negative steric interactions otherwise. As the crystal struc-
ture of R (Palczewski et al., 2000) subsequently revealed
that helix 3 was highly tilted, this might not be the case.
It has been implicated that all of the cytoplasmic do-
mains, except for the first loop connecting helices 1 and 2,
are involved in the interaction with Gt (Hamm et al., 1988;
Hargrave et al., 1993). Tyr136-Val139 in loop 2, Glu247-
Thr251 in loop 3 (Acharya et al., 1997), Asn310-Gln312 in
loop 4 (Marin et al., 2000; Ernst et al., 2000) (the crystal
structure revealed an eighth helix running parallel to the
disk membrane), and the C-terminal tail (Takemoto et al.,
1986; Phillips and Cerione, 1994) have been pointed out as
potential interaction sites by mutational analysis and peptide
competition assay. On transducin, both Gt and Gt com-
plex appear to contact with R*. The N-terminal 23 residues,
internal sequence, and the C-terminal 11 residues in Gt
(Hamm et al., 1988) and the C-terminal 12 residues of
Gt (Kisselev et al., 1995) are the known sites of inter-
action. It was demonstrated that synthetic peptides cor-
responding to the C-termini of Gt (IKENLKDCGLF)
and Gt (DKNPFKELKGGC-farnesylated) bind to R*
and stabilize Meta II, mimicking the effect of Gt.
The R*-bound structure of Gt(340–350) has been de-
termined by transferred nuclear Overhauser effect (TrNOE)
NMR spectroscopy (Dratz et al., 1993; Kisselev et al.,
1998). In the case of the studies by Dratz et al. (1993), the
peptide used was an analog (IRENLKDCGLF) with higher
affinity for R*. This higher affinity appears to have an
exchange rate far from the optimum for the TrNOE exper-
iment resulting in suboptimal spectra leading to a mis-
assignment of resonances and a wrong conclusion concern-
ing the R*-bound structure that was ultimately
acknowledged (Dratz et al., 1997). The native sequence
used by us (Kisselev et al., 1998) has the exchange charac-
teristics appropriate for obtaining optimal TrNOE spectra,
and the resulting structure is unambiguous. When a higher-
affinity analog (VLEDLKSCGLF) was subjected to the
same experimental conditions, little useful information was
obtained. In summary of the results obtained by Kisselev et
al. (1998), Gt(340–350) binds to photoactivated rhodopsin
to form a continuous helix terminated by a reverse glycine
C-cap turn (Schellman, 1980) with a distinctive hydropho-
bic cluster of the side chains of two leucines, a lysine, and
a phenylalanine. Based on the conservation of these residues
in most subclasses of G-proteins, this motif may be of
significance in GPCR/G-protein interactions, at least for the
rhodopsin family of GPCRs. In fact, the corresponding
C-terminal region in the crystal structure of Gi, rhodopsin-
family G-protein (Tesmer et al., 1997), showed identical
conformation to the TrNOE-derived structure (Kisselev et
al., 1998). Nevertheless, Hamm and her colleagues (Aris et
al., 2001) continue to question the results from the Kisselev
et al. (1998), citing inherent problems in interpretation of
TrNOE experiments. To confirm the relevance of the
TrNOE-derived structure of Kisselev et al. (1998), we de-
cided to stabilize the deduced conformation by chemical
modification to determine if Meta II stabilization was re-
tained in such analogs.
Structure-activity studies have been carried out on the
Gt(340–350)-rhodopsin system by a combinatorial ap-
proach using phage display and random single amino-acid
substitution of the IKENLKDCGLF sequence (Martin et al.,
1996; Aris et al., 2001). The results revealed that substitu-
tion of Lys341 with a Leu markedly improved binding. This
is in agreement with the hypothesis that the protonated side
chain of Lys341 plays a crucial role in the hydrophobic
cluster, providing an energy cost of deprotonation upon R*
binding to maintain the affinity of transducin within the
optimal range for its biological role. Further evidence that
Lys341 binds in the unprotonated state comes from studies
on a series of Phe350 mutation analogs with para-Phe
substituents (Sha et al., 2001). The availability of the ex-
perimental data (Kisselev et al., 1998) on the three-dimen-
sional structure of the Gt(340–350) enabled us to investi-
gate the structure-activity relationships in greater detail.
Thus, we have designed 14 peptides based on the TrNOE
structure (Kisselev et al., 1998). The analogs were designed
to stabilize the peptide-backbone structure and vary in their
surface structure, so that the binding site of R* could be
probed. Starting with the crystal structure of R, the struc-
tural change upon light activation was simulated based on
current experimental data to generate a model of the R*
structure. Molecular docking technique was then able to
build hypothetical complexes of Gt(340–350)/R* that are
feasible sterically and electrostatically. When affinity pre-
dictions using VALIDATE (Head et al., 1996) for the
hypothetical complexes were compared with the measured
affinities, the plausibility of the models could be evaluated.
From these studies, atomic-resolution models of the inter-
face between R* and transducin are proposed.
EXPERIMENTAL PROCEDURES
Design of peptide analogs
A list of the designed analogs is shown in Table 1. The disulfide bridges
of analogs 1c and 2c were used to stabilize the glycine C-cap turn moiety
(Schellman, 1980). The penicillamine (Pen) in analog 1 is for retaining the
hydrophobicity of the Leu349 side chain due to the two methyl groups and
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provides a site for disulfide constraint. The Pro-D-NMeAla dipeptide
sequence of analog 3 has previously been predicted (Chalmers and Mar-
shall, 1995; Takeuchi and Marshall, 1998) to have a high reverse turn
propensity in aqueous media by Monte Carlo/stochastic dynamics calcu-
lations (Guarnieri and Still, 1994). Because a peptide with Gly348 replaced
with D-Ala (analog 5) has been shown to retain full activity (Dratz et al.,
1993), the use of a D-Ala derivative seemed justified. 3-Mercaptoproline
(3Mpt) (Kolodziej et al., 1995) in analog 4 combines the high turn pro-
pensity of proline with the required side chain functionality of cysteine.
Analog 6c contains a helix-stabilizing disulfide bond in the helical region
of Gt(340–350). 1-Aminoisobutyric acid (Aib, -methylalanine) has long
been known (Marshall and Bosshard, 1972; Hodgkin et al., 1990) to favor
helical secondary structures as a result of deletion of allowed conforma-
tional regions in the Ramachandran plot due to the bulk imposed by the
-methyl groups. Thus, three of the residues in the helical region were
substituted by Aib in analog 7. Amide bond formation between the side
chains of Lys and Glu (analog 8) or Asp has been reported to provide up
to 30-fold gain in binding energy (Miranda et al., 1997) due to a decrease
in the conformational entropy of a helical peptide segment. Highly popu-
lated helices with reduced temperature dependence have also been ob-
served on circular dichroism spectra for similar sequences. As removal of
the positive charge carried by the amino side chain of Lys341 from the
hydrophobic cluster has been reported to increase the affinity (Martin et al.,
1996; Aris et al., 2001) (analogs 9 and 11), elimination of the closely
positioned negatively charged carboxyl C-terminus (analog 10) may give
rise to a similar effect by reduction of the desolvation free energy. Potential
roles of the side chains of Cys347 and Leu349 were examined by point
mutations in peptides 12–14.
Initial structures of the analogs were built by modifying the R*-bound
structure (Kisselev et al., 1998). The GB/SA continuum model (Still et al.,
1990) was used with extended electrostatics and force field charges to
simulate aqueous solvation. The ring systems in the analogs possessing
constrained cyclic motifs were subjected to Monte Carlo/molecular dy-
namics search (Guarnieri and Still, 1994) to explore all energetically
reasonable conformations. Amide bonds were kept in the trans conforma-
tion while all other torsional angles between heavy atoms were varied by
60°–180° in each Monte Carlo move. The structures within 30 kcal/mol
from the global minimum were compared with the corresponding region of
the TrNOE structure. This procedure was able to isolate unfavorable ring
designs. All calculations were carried out using Macromodel 5.5 (Mo-
hamadi et al., 1990) with the Amber94 force field (Cornell et al., 1995) on
Silicon Graphics Indigo R4000 and R10000 workstations.
Peptide synthesis
Analog peptides were synthesized with standard solid-phase methodology
by manual or automatic Fmoc strategy. Coupling was facilitated by O-ben-
zotriazol-1-yl-N,N,N,N-tertamethyluronium tetrafluoroborate/1-hydroxy-
benzotriazole/diisopropylethylamine (TBTU/HOBt/DIEA) reagents, and
25% piperidine in N,N-dimethylformamide was used for deprotection. The
crude peptides were released from the Wang-resin (2-Cl-trityl-resin for
analog 10) by the following cocktail: 90% trifluoroacetic acid (TFA), 5%
water, 2.5% 1,2-ethandedithiol (EDT), 2.5% anisole. For the methionine-
containing peptides (analogs 9 and 10), anisole was replaced by thioani-
sole. Analog 4 was synthesized on the Merrifield-resin and isolated as a
mixture of two diastereomers. Boc-protected trans-3-(p-methylbenzylmer-
capto)proline (Kolodziej et al., 1995) was coupled manually (two-fold
excess) with TBTU/HOBt/DIEA reagents overnight. The Boc group was
removed by 50% TFA/dichloromethane, and the synthesis was completed
on the ACT396 synthesizer (Advanced ChemTech, Louisville KY). Ana-
log 8 was synthesized on the Merrifield-resin. The peptide was treated with
TFA after coupling Glu342, to remove the protecting groups of the two
side chains (Glu342 and Lys345) whereas all other protecting groups
including the linker to the resin remained intact. The two side chains were
cyclized with TBTU/HOBt/DIEA, and then the synthesis of the protected
cyclic peptide was completed on the resin support. Final cleavage of
analogs 4 and 8 was done with HF (2.5% anisole, 2.5% EDT) for 1 h at
0°C. The disulfide bridges were formed by stirring the crude peptides in
20% dimethylsulfoxide/water solution for 12 h, and then the mixtures were
lyophilized. All crude peptides were purified to 95% purity by prepara-
tive reverse-phase high-performance liquid chromatography (HPLC) using
C4 or C18 column (solvent A: 0.1% TFA in H2O; solvent B: 100%
acetonitrile; gradient: 20–55% in 20 min). Methionine-containing peptides
were chilled to 78°C immediately after fraction collection because of
their observed susceptibility to oxidation. The pure peptides were eluted at
37–47% B and analyzed by electrospray mass spectrometry. Criteria to
establish purity were 95% peak area in analytical HPLC and no peak in
the mass spectrum besides the target molecular weight, double-, triple-
charged, and sodium- or potassium-complexed peaks.
UV/visible spectroscopy
The binding affinities of the analog peptides were measured using a
Meta II stabilization assay (Kisselev et al., 1995) by UV/visible spec-
troscopy. The assay samples contained 100 g/ml (2.5 M) of
rhodopsin in rod outer-segment membranes, prepared as described
(Papermaster and Dreyer, 1974; Yamazaki et al., 1982), and analog
peptides in buffer A (pH 8.0, 20 mM Tris/HCl, 130 mM NaCl, 1 mM
MgCl2, 1 M EDTA, 2 mM dithiothreitol (DTT)). The assays were
done with and without DTT for analogs containing disulfide constraints.
With DTT, the peptide solutions (in buffer A) were incubated for 3 h
under N2 at room temperature before the experiment to break the
disulfide bonds. The samples were kept on ice at 0°C and prepared
under dim red light or in the dark to avoid premature bleaching of
rhodopsin. The absorption spectrum of dark-adapted rhodopsin was
taken, and rhodopsin was activated by 490  5 nm light for 20 s,
followed by a scan acquiring the second spectrum, using a Cary50
spectrophotometer (Varian, Palo Alto, CA). The cuvette compartment
was maintained at 4°C. The measurements were repeated with increas-
ing concentration of analog peptides from 1 M up to 5 mM. The Meta
II stabilization was calculated as A380 nm  A417 nm, where A is the
absorbance change before and after light activation.
Modeling photoactivated rhodopsin
As some of the residues in loop 3 of dark-adapted rhodopsin are
disordered in the crystal structure (Palczewski et al., 2000), they were
TABLE 1 Structures and binding affinities of the
synthetic peptides
Analog structure
EC50
DTT (c) DTT
1c, 1 IKENLKDcyclo(CGPen)F 5 mM 10 mM
2c, 2 IKENLKDcyclo(CGC)F 10 mM 10 mM
3 IKENLKDP(D-NMeAla)LF 10 mM
4 IKENLKD(3Mpt)GLF 10 mM
5 IKENLKDC(D-Ala)LF 400 M
6c, 6 IKEcyclo(CLKDC)GLF 10 mM 200 M
7 AibKAibAibLKDCGLF 700 M
8 IKcyclo(ENLK)DCGLF 70 M
9 MLENLKDCGLF 25 M
10 MLENLKDCGLF-CH2OH 75 M
11 VLEDLKSCGLF 5 M
12 IKENLKDSGLF 10 mM
13 IKENLKDCGIF 6 mM
14 IKENLKDCGTleF 9 mM
15 Gt(340–350); IKENLKDCGLF 500 M
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restored with standard loop reconstruction approaches (Galaktionov et
al., 2001) to provide a complete atomic resolution model of R. A model
of the R* structure was obtained by moving helix 6 (Lys245-Phe276) in
the crystal structure (Palczewski et al., 2000) of R. A rigid-body motion
of helix 6 was predicted by EPR experiments (Farrens et al., 1996)
measuring the distances between residues on the cytoplasmic ends of
the helices 3 and 6, before and after light activation of rhodopsin. In
columns 1 and 2 of Table 2, EPR-measured values (Farrens et al., 1996)
for R and the corresponding distances in the x-ray crystal structure
(Palczewski et al., 2000) are listed. Although the relative distances are
similar, the absolute values of the distances are quite different. This is
likely because distances were measured between the -carbons (Cs) in
the crystal structure (Palczewski et al., 2000), whereas EPR used
nitroxide spin labels located five rotatable bonds away from the Cs
(Farrens et al., 1996). This problem is exemplified in the distance
between two spin labels on Cys140 and Cys316 estimated at 37 Å
(Delmelle and Virmaux, 1977) when the measured distance between the
two Cs in the crystal structure is only 29 Å. The experimental data
with R* (column 3) was scaled to improve the correspondence between
EPR data and crystal structure measurements, to obtain the target
distances (column 4) using the following formula:
EstimatedR* EPRR* 	x-rayR/EPRR
.
Helix 6 with a part of the cytoplasmic loop 3, consisting of Ser240-Phe276,
was moved to a location where the root mean square error from the target
distances and the deviation from the crystal structure were both minimized.
The amide bond of Phe276 to Thr277 was then restored, and the residues
Gln236-Glu239 (missing in the crystal structure) were modeled (Galak-
tionov et al., 2001) in between Ser240 of R* and Ala235 of R. The crystal
structure of dark-adapted rhodopsin was, thus, minimally modified to
include the experimentally observed changes by EPR (Farrens et al., 1996)
in the relative positions of helices 3 and 6. The structures of cytoplasmic
loop 3 and extracellular loop3 were energy minimized with the Kollman
force field (Hall and Pavitt, 1984), allowing residues Gln236-Thr243 and
275–281 to accommodate the impact of helix 6 movement. The molecular
modeling was performed using Sybyl 6.5 (Tripos, St. Louis, MO) on a
Silicon Graphics Indigo R10000 workstation.
Modeling the R*-Gt interface
The TrNOE structure of Gt(340–350) was docked as a rigid body into the
cytoplasmic face of modeled R*, consisting of four loops, Tyr60-Leu76,
Val130-Thr160, Gln225-Arg252, and Ile305-Cys322, using FTDOCK pro-
gram (Gabb et al., 1997). The C-terminal segment after the palmitoylation
sites at Cys322 and Cys323 was omitted because 1) its structure is not well
defined as the crystal structure is missing residues Leu328-Ala333 and 2)
the segment of Ser334-COOH is distant from the hypothetical binding site
described below. Gt(340–350) was scanned over the space around the
R*-loops, exploring the six degrees of freedom at a resolution of 1.2 Å and
20°. Structures of the complexes were scored by the surface correlation
between Gt(340–350) and R*-loops, and ones with unfavorable charge
interactions were discarded. At every translation, the 10 best-scoring
complexes were kept for further evaluation. There were usually more than
3000 structures at this step. To extract feasible structures, the following
filtering procedure was employed. First, complexes where Cys347,
Leu349, or Phe350 of Gt(340–350) were in contact with any atom(s) in
R*-loops were retained in accord with experimental observation, which
assures that Gt would be in the right orientation; i.e., the rest of Gt is placed
in the cytoplasm. Second, two potential binding sites on R*, formed by
loops 2 and 3 and by loops 3 and 4, were explored based on mutational
studies (Acharya et al., 1997; Marin et al., 2000; Ernst et al., 2000).
Complexes where Val138 or Val139 of R* was in contact with any atom(s) in
Gt(340–350) for the first binding mode, and anywhere in the R*-segments of
Asn310-Gln312 and Lys245-Gln247 were in proximity to Gt(340–350) for
the second binding mode, were kept for further evaluations. Finally, the crystal
structures of Gt-trimer (Lambright et al., 1996) and the modeled R* were
fused with Gt(340–350) and the R*-loops in the complexes, and any struc-
tures with Gt-R* collisions were discarded as physically impossible. For
comparisons, the same procedure was performed with Gt(340–350) and the
loop-complex derived from dark-adapted rhodopsin.
Binding-affinity prediction
The binding affinities of the analog peptides as well as Gt(340–350) were
calculated. The structures of the peptides were aligned with Gt(340–350)
in the docked complexes, and the structures of the interfaces between R*
and the peptides were energy minimized using Macromodel 6.5 (Mo-
hamadi et al., 1990) with the Amber94 force field (Cornell et al., 1995).
The VALIDATE program (Head et al., 1996) was then used to calculate the
properties of the minimized complexes, charges, induction energy, and hydro-
phobic/hydrophilic contact-surface that were used to estimate the binding
affinities. The partial least square of latent variables (PLS) (Wold et al., 1993)
model of affinity calibrated with 65 crystalline complexes of known affinities
available in VALIDATE was applied to the modeled complexes, and the
binding affinities of the peptides were predicted. All the calculations were
carried out on Silicon Graphics Indigo R4000 and R10000 workstations.
RESULTS
Fig. 1 shows the measurements and the fitted dose-response
curves for active peptides. The EC50 values for all the
analog peptides were calculated and listed in Table 1. No
Meta II stabilization effect was observed for the analogs
marked as 10 mM, up to 5 mM concentration. Fig. 2
shows the structural changes in the crystal structure of
rhodopsin proposed to occur upon activation to generate the
R* state based on imposing the changes in distances seen by
the EPR measurements. Seven complex structures were
found by molecular docking of Gt(340–350) into the mod-
eled R*-loops as shown in Fig. 3, whereas docking with
R-loops derived from the crystal structure yielded none. The
measured binding affinities were compared with the predic-
tions to evaluate the structures derived by molecular modeling.
Fig. 4 shows the comparisons for the seven complexes (a–g)
and a control complex (h), where the N-terminus of the peptide
that connects to the rest of Gt is pointing into the binding
pocket. The values of the experimental data for inactive ana-
logs (10 mM) were set to zero; i.e., EC50  1 M. To
quantitatively compare the modeled structures, correlation co-
efficients were calculated between predicted and observed
affinities. Listed in Table 3 are the correlation coefficients for
TABLE 2 Distances between Val139 and Lys248 to Arg252
Val139 to
EPR
R
X-ray
R
EPR
R*
Estimated
R*
Model
R*
Lys248 12–14 8.5 23–25 15.6 14.4
Glu249 15–20 11.5 15–20 11.5 11.5
Val250 15–20 10.35 12–14 8.5 10.1
Thr251 12–14 8.33 23–25 15.6 13.8
Arg252 15–20 11.5 23–25 15.6 14.8
*Distances are in angstroms.
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all the analogs, and with the inactive analogs (no experimental
measurement of affinity) excluded.
DISCUSSION
Constrained analogs of the Gt(340–350)
As seen with analogs 6, 9, 10, and 11, enhancing the
hydrophobicity of the hydrophobic cluster at the C-cap turn
by changing residues into more hydrophobic amino acids
improved activities, suggesting that hydrophobic interaction
of this moiety of Gt(340–350) with R* is the driving force
for R* binding. The higher activity of analog 9 over 10 may
indicate that a specific interaction between the carboxyl
group of Phe350 and R* exists, consistent with a previous
study (Osawa and Weiss, 1995). Analog 7 with rather strong
helical constraints retained almost full activity, confirming
the TrNOE structure (Kisselev et al., 1998) and the insig-
nificance of the side chains of Ile340, Glu342, and Asn343
in specific interactions. The improved affinity of analog 8
where the helical turn of Glu342-Lys345 was locked by the
amide bond indicates that preorganization of the receptor-
bound conformation is beneficial. Analog 12 with a point
mutation of Cys347Ser completely lost its activity. Also, all
the analog peptides with the sulfhydryl of Cys347 blocked
due to the intrapeptide disulfide bonds (analogs 1c, 2c, and
6c) showed very little activity, if any. Furthermore, the
activity of Gt(340–350) was lower (EC50  1 mM, data
not shown) when the assay was done without DTT. This can
be explained as a result of oxidation of the sulfhydryl at
Cys347 to form disulfide dimers, as pH 8 favors sulfhydryl
oxidation. These results strongly argue that Cys347 is an
important recognition site for R* binding. Analog 3 was
inactive presumably due to its Cys347Pro substitution, not
to the helical constraint or the extra volume requirements of
D-NMeAla. The 3Mpt347 in analog 4 has a sulfhydryl
group, but the five-membered ring of proline to which the
FIGURE 1 Dose-responses of Meta II stabilization for the active analogs
(1c, 5, 6, 7, 8, 9, 10, 11, 13, and 14) and Gt(340–350) normalized by the
saturation level. Measurements were fitted with the equation: Meta II 
peptide concentration/(peptide concentration  EC50) to obtain EC50 val-
ues of the peptides.
FIGURE 2 Probable structural change of rhodopsin induced by light
activation. Helix 6 was moved (R:yellow  R*:green) as suggested by the
distance measurement by EPR (Farrens et al., 1996). (a) Side view; (b)
View from cytoplasmic space. The opening between cytoplasmic loops 2
(shown in yellow) and 3 (yellow  green) widens with this structural
change, creating a probable binding site for the -subunit of transducin.
FIGURE 3 Structures of the complex between Gt(340–350) and cyto-
plasmic loops of R* consisting of Tyr60-Leu76, Val130-Thr160, Gln225-
Arg252, and Ile305-Cys322, obtained by molecular docking (Gabb et al.,
1997). The surface correlation between R*-loops and Gt(340–350) was
scored for each of seven model complexes by FTDOCK as follows (in
arbitrary units): 53 (a), 51 (b), 46 (c), 45 (d), 37 (e), 36 (f), and 29 (g).
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sulfhydryl is attached is highly constrained. Therefore, it is
likely that the sulfhydryl is not pointing in the right direc-
tion to correctly interact with R* or that the increased steric
bulk of the analog is not tolerated by R*. In this study, our
attempt to constrain the C-cap turn (analogs 1c and 2c)
failed because of the loss of Cys347 side chains due to the
intrapeptide disulfide bonds. However, we have recently
shown that a cyclic peptide with amide bond between
Phe350 (NH2 at the para position of the phenyl ring) and
the Glu341 carboxyl group stabilizing the reverse turn had
significantly improved binding affinity (Sha et al., 2001).
Leu349 was found to be another invariable residue as pre-
viously reported (Osawa and Weiss, 1995). Mutations of
Leu349Pen in analog 1, Leu349Cys in analog 2, Leu349Ile
in analog 13, and Leu349Tle in analog 14 all significantly
reduced activities. This result is particularly striking be-
cause leucine, isoleucine, and tert-leucine are isomers, so
that their chemical properties are quite similar. They differ
only in their arrangement of the carbon backbone in the side
chains, leading to the hypothesis that the side chain of
Leu349 is in intimate contact with R*.
In summary, from the point of Gt(340–350), hydropho-
bic interaction between the binding site on R* and the
hydrophobic cluster at the C-cap turn is the major force for
the binding, and Cys347 and Leu349 seem to have direct
surface contact with photoactivated rhodopsin.
Model of photoactivated rhodopsin
In adapting the crystal structure of dark-adapted rhodopsin to
the photoactivated state (R*), helix 6 was rotated and tilted
outward centered near Ile275-C at the extracellular end of
helix 6. As a result of this movement, the opening between the
cytoplasmic loops 2 and 3 was widened, which we believe
creates the binding site for Gt. Although the cytoplasmic end of
helix 6 changed its location by 5 Å, the translational move-
ment of the extracellular end was only0.4 Å. The rest of the
molecule was kept unchanged. We have chosen to move only
helix 6 because this is the only part of the R* for which
movement is supported by quantitative experimental data.
Struthers et al. (2000) showed that a highly constrained rho-
dopsin, in which four disulfide bonds were restricting the
movements of the helices, could activate Gt, indicating that in
the cytoplasmic side, only helices 2, 4, and/or 6 were required
to move for active R* formation. Yang et al. (1996) observed
that the cytoplasmic ends of helices 1 and 6 moved apart by 5
Å upon light activation, but the experiment by Struthers et al.
(2000) showed that this movement is not a requirement. It is
quite possible that other helices also move, and there exists
some circumstantial evidence (Abdulaev and Ridge, 1998;
Borhan et al., 2000; Farahbakhsh et al., 1995), but the move-
ment cannot be determined quantitatively for molecular mod-
eling at this time. In accord with the model, the EPR experi-
ments of Delmelle and Virmaux (1977) showed no changes in
the distance between a spin label on Cys140 at the C-terminus
of helix 3 and another spin label on Cys316 in the middle of
helix 8 upon light activation. One must remember, however,
that the absence of detection of movement may simply reflect
the lack of sufficient sensitivity using the spin-label approach.
Another reason that a movement of helix 6 is plausible is that
helix 6 contains Trp265, which forms a cross-link with a
photoaffinity analog of the ionone ring of 11-cis retinal in R.
When light energy isomerizes 11-cis retinal to all-trans retinal,
the cross-link to helix 6 is not formed, and the ionone ring
FIGURE 4 Comparisons between measured (solid bars) and predicted
(hatched bars) affinities of the peptides for models (a–h). Measurements
for the inactive analogs (2, 2c, 3, 4, 6c, and 12) were set to EC50  1 M.
VALIDATE (Head et al., 1996) was used to predict affinities.
TABLE 3 Correlation coefficients between the prediction
and the experiment
Model All analogs Active analogs
a 0.71 0.90
b 0.57 0.79
c 0.54 0.86
d 0.56 0.81
e 0.45 0.80
f 0.58 0.89
g 0.61 0.75
Control 0.41 0.50
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points instead toward helix 4 (Borhan et al., 2000). The dis-
tances between Val139 and Lys248-Arg252 in the modeled R*
structure are listed in the column 5 of Table 2. The root mean
square error from the estimated target distances was 1.1 Å.
Model of R*/Gt(340–350) complex
Apparently, the movement of helix 6 according to experimen-
tal data generated a reasonable model of light-activated rho-
dopsin as it successfully created a binding site for Gt(340–
350) in accord with experimental observation (Franke et al.,
1990; Acharya et al., 1997). In all of the resultant complexes,
Gt(340–350) binds to the site in between loops 2 and 3,
indicating there is not enough space between loops 3 and 4 in
our R*-model for complex formation. The seven binding
modes differ basically in the orientation around the helical axis
of Gt(340–350) and can be sorted into three structural
groups. In complexes b, d, and e, the C-terminus is pointing
toward the bottom of helix 6, Glu247-Lys248. Leu349 and
Phe350 are well in the pocket formed by loops 2 and 3, and
closer to loop 2 rather than loop 3. In the second structural
group, consisting of a and c, Gt(340–350) is turned slightly
clockwise (viewed from the cytoplasmic side), compared with
the first group, into the binding pocket, bringing Leu349 close
to the N-end of loop 3. In complexes f and g, Gt(340–350) is
further turned clockwise until its C-terminus points away from
the binding pocket. Cys347-Leu349 is close to the amino end
of loop 2, but loop 3 is now distant from any part of the
peptide. There is a cluster of hydrophobic residues in the
binding site (137VVVC140) appropriate for the hydrophobic
interaction with Gt, consistent with the experimental results.
Leu349, as being close to the helical axis, is in the binding
pocket in all models, and Cys347 is within the binding site in
two of the models, g and f.
Koenig et al. (2000) reported that the N-H vectors of
Leu344 and Gly348 make angles of 48  4° and 40  8°,
respectively, with the disk normal by measuring residual di-
polar coupling between rhodopsin-containing disk membrane
and an analog peptide (IRENLKDSGLF). Complexes a, f, and
g are in relatively good agreement (L344: 60°, 52°, 52°; G348:
49°, 36°, 42°, respectively), and in the other complexes, the
angles are more than 20° off for Leu344 and 10° off for
Gly348. Because it is unclear how the mutations of Lys341Arg
and Cys347Ser affected the R* binding and/or the bound
structure of the peptide, and the membrane’s relative location
to rhodopsin contained error in our angle measurement (helix
4 was used as the membrane normal), this experimental result
does not necessarily disprove models that do not quantitatively
agree.
There have been mutational studies (Acharya et al.,
1997) identifying Tyr136-Val139 in loop 2 and Glu247-
Thr251 in loop 3 as interaction sites with Gt. Khorana’s
group showed that Glu342-Lys345 (as well as Leu19-
Arg28 and Arg310-Lys313) of Gt cross-linked to
Ser240Cys in loop 3 of rhodopsin upon light activation
(Cai et al., 2001; Itoh et al., 2001). All of the modeled
complexes possibly have interactions between Gt(340–
350) and loop 2 and/or loop 3 because of the way the
docked structures were filtered (see Experimental Proce-
dures); particularly Tyr137-Val139 seems to be literally
facing the hydrophobic cluster of Gt(340–350). Another
study (Ernst et al., 2000; Marin et al., 2000) has shown
that Asn310-Gln312, the amino end of helix 8, interacts
with Gt(340–350). Obviously, in none of the complexes
would Gt(340–350) be able to directly interact with
helix 8. As it is difficult to distinguish between direct and
indirect effects from mutational studies, our models do
not necessarily conflict with these experimental results. It
is quite possible that the interaction of Gt with loop 3
causes conformational changes in helix 8. Or else, helix
8 is holding loop 3 stabilizing the binding pocket as the
structural change proposed here brings loop 3 closer to
the N-terminus of helix 8; therefore, rhodopsin with
mutation in helix 8 may fail to form the binding site.
The C-terminal region of Gt is also known to bind to
photoactivated rhodopsin and stabilize Meta II conforma-
tion (Kisselev et al., 1995). However, in our models, the
-subunit would not be able to contact with the receptor,
regardless of the peptide orientation. The distance between
C-termini of the -subunit and -subunit is 45 Å as
measured in the crystal structure of Gi heterotrimer
(Lambright et al., 1996), whereas the receptor is 43 Å across
(radius  22 Å). One possible explanation for this discrep-
ancy is sequential binding of the two sites (Kisselev et al.,
1999). Receptor dimerization is another possibility; there
may be an adjacent rhodopsin for direct interaction with the
-subunit, next to the one bound to the -subunit.
Evaluation of the models
Although the accuracy of absolute affinity prediction is
problematic, prediction of relative affinities is more reliable.
Thus, the overall correlation between predicted affinity and
experimental observation of a series of active analogs could
be used to estimate the probability that a given binding
mode is plausible. The strongest correlation to the experi-
mental data seen in Table 3 was found with complex a,
using either way of treating the data (either including the
inactive analogs or not). It is also the complex of best
surface correlation, supporting the hypothesis that the hy-
drophobic interaction is crucial. The control complex with
the peptide orienting the -subunit to overlap the receptor
shows the weakest correlation as expected, and its value
(0.5) can roughly estimate the noise level of this proce-
dure, below which a critical evaluation cannot be made.
When the inactive analogs were excluded, discrimination of
control complex against the plausible structures became
much more obvious, and two additional complexes (c and f)
show strong correlation to the experimental data as well as
does complex a. Presumably, the values with only the active
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analogs are more reliable than values with all analogs be-
cause 1) the binding affinities for the inactive analogs (zero)
are not measured values, but lack of activity at an arbitrary
concentration limitation and 2) lack of measured activity of
some analogs may be due to experimental conditions (lim-
ited solubility, for example). After all, in the case that a
ligand does not bind to the receptor, which we observed for
the analogs missing the Cys347 side chain, the affinity
prediction based on the structure of the complex is not
useful. The role of Cys347 side chain might be a necessary
recognition site in an earlier stage of the binding process,
rather than stabilizing the final complex; thus the locations
of Cys347 in all models do not correlate with the experi-
mental observation suggesting that the sulfhydryl group of
Cys347 is in intimate contact with R*.
The correlation coefficients of a, c, and f are quite close,
indicating that the sensitivity of this model-evaluation process
is not sufficient to determine the precise orientation of
Gt(340–350) in the binding pocket. This problem may be
overcome by testing additional analogs, thus widening the
variety in the surface structures of analogs probing the receptor
cavity, because the relative orientations of the peptides within
the cavity make differences in the properties of the complex
that VALIDATE computes (Head et al., 1996). Determining
the precise orientation of Gt would greatly help us to under-
stand the relative orientation of the rhodopsin with respect to
transducin in the complex and impose constraints on possible
receptor-dimer formation. Yet, the binding site on R* seems to
be confirmed by the experimental results, as the modeled
complexes show such a strong correlation to the measurement
for as many as 18 (12 active) analog peptides of wide affinity
(5 M to 10 mM, 2000-fold range in activities).
CONCLUSIONS
A comprehensive approach utilizing biophysical measure-
ments (both crystal and TrNOE structures and EPR-distance
measurements), structure-activity studies, molecular modeling,
and affinity prediction yields plausible structural models of the
interaction between R* and transducin. The exposure of a
binding site and strong correlation between experimental and
estimated affinity found for the set of constrained peptide
analogs supports the low-resolution model of the photoacti-
vated state generated from the crystal structure of dark-adapted
rhodopsin by movement of helix 6. The resultant hypothetical
complexes are consistent with a number of experimental data
from mutational studies on both transducin and rhodopsin as
well as biophysical studies measuring the orientation of NH
vectors of the bound Gt-peptide (Koenig et al., 2000) not used
in their construction. These models provide guides in design-
ing experiments to further explore the details of the mechanism
of signal transduction that should eventually enable us to
control these clinically important systems. For example, dis-
tance measurements between certain atoms will be able to
orient Gt correctly in the binding pocket. The distance between
specific sites can be estimated by NMR, EPR, and various
cross-linking techniques using derivatized rhodopsin, transdu-
cin, and synthetic peptides (work in progress). Finally, this
comprehensive approach to evaluating protein complexes can
be applied to other systems where direct structural-determina-
tion methods (x-ray crystallography and NMR spectroscopy)
are problematic.
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